Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) amplification or overexpression occurs in approximately 20% of advanced gastric or gastro-oesophageal junction adenocarcinomas1,2,3. More than a decade ago, combination therapy with the anti-HER2 antibody trastuzumab and chemotherapy became the standard first-line treatment for patients with these types of tumours4. Although adding the anti-programmed death 1 (PD-1) antibody pembrolizumab to chemotherapy does not significantly improve efficacy in advanced HER2-negative gastric cancer5, there are preclinical6,7,8,9,10,11,12,13,14,15,16,17,18,19 and clinical20,21 rationales for adding pembrolizumab in HER2-positive disease. Here we describe results of the protocol-specified first interim analysis of the randomized, double-blind, placebo-controlled phase III KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for unresectable or metastatic, HER2-positive gastric or gastro-oesophageal junction adenocarcinoma22 (https://clinicaltrials.gov, NCT03615326). We show that adding pembrolizumab to trastuzumab and chemotherapy markedly reduces tumour size, induces complete responses in some participants, and significantly improves objective response rate.
Your institute does not have access to this article
Open Access articles citing this article.
Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter
Updates in Surgery Open Access 14 July 2022
Holistic Integrative Oncology Open Access 28 April 2022
Outcome and prognostic factors in patients undergoing salvage therapy for recurrent esophagogastric cancer after multimodal treatment
Journal of Cancer Research and Clinical Oncology Open Access 19 April 2022
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD) is committed to providing qualified scientific researchers access to anonymized data and clinical study reports from the company’s clinical trials for the purpose of conducting legitimate scientific research. MSD is also obligated to protect the rights and privacy of trial participants and, as such, has a procedure in place for evaluating and fulfilling requests for sharing company clinical trial data with qualified external scientific researchers. The MSD data-sharing documentation (http://engagezone.msd.com/ds_documentation.php) outlines the process and requirements for submitting a data request. Feasible requests will be reviewed by a committee of MSD subject matter experts to assess the scientific validity of the request and the qualifications of the requestors. In line with data privacy legislation, submitters of approved requests must enter into a standard data-sharing agreement with MSD before data access is granted. Data will be made available for request after product approval in the US and EU or after product development is discontinued; an exception will be made for this ongoing trial such that data will be made available for request after the protocol-specified primary endpoint analyses have been reported. There are circumstances that may prevent MSD from sharing requested data, including country or region-specific regulations. If the request is declined, it will be communicated to the investigator. Access to genetic or exploratory biomarker data requires a detailed statistical analysis plan that is collaboratively developed by the requestor and MSD subject matter experts; after approval of the statistical analysis plan and execution of a data-sharing agreement, MSD will either perform the proposed analyses and share the results with the requestor or will construct biomarker covariates and add them to a file with clinical data that is uploaded to a SAS portal so that the requestor can perform the proposed analyses.
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–209 (2014).
Van Cutsem, E. et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18, 476–484 (2015).
Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169–175 (2017).
Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687–697 (2010).
Shitara, K. et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 6, 1571–1580 (2020).
Gall, V. A. et al. Trastuzumab increases HER2 uptake and cross-presentation by dendritic cells. Cancer Res. 77, 5374–5383 (2017).
Park, S. et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18, 160–170 (2010).
Taylor, C. et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin. Cancer Res. 13, 5133–5143 (2007).
zum Buschenfelde, C. M., Hermann, C., Schmidt, B., Peschel, C. & Bernhard, H. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res. 62, 2244–2247 (2002).
Chaganty, B. K. R. et al. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion. Cancer Lett. 430, 47–56 (2018).
Varadan, V. et al. Immune signatures following single dose trastuzumab predict pathologic response to preoperative trastuzumab and chemotherapy in HER2-positive early breast cancer. Clin. Cancer Res. 22, 3249–3259 (2016).
Triulzi, T. et al. HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy. Oncoimmunology 8, e1512942 (2019).
Triulzi, T. et al. Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit. Br. J. Cancer 119, 1487–1494 (2018).
Stagg, J. et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl Acad. Sci. USA 108, 7142–7147 (2011).
Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050–1059 (2007).
Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors. Nat. Med. 15, 1170–1178 (2009).
Tesniere, A. et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29, 482–491 (2010).
Mortenson, E. D., Park, S., Jiang, Z., Wang, S. & Fu, Y. X. Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells. Clin. Cancer Res. 19, 1476–1486 (2013).
Muller, P. et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci. Transl. Med. 7, 315ra188 (2015).
Janjigian, Y. Y. et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 21, 821–831 (2020).
Rha, S. Y. et al. Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC). J. Clin. Oncol. 38, abstract 3081 (2020).
Chung, H. C. et al. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future Oncol. 17, 491–501 (2021).
Barrueto, L. et al. Resistance to checkpoint inhibition in cancer immunotherapy. Transl. Oncol. 13, 100738 (2020).
Shitara, K. et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 392, 123–133 (2018).
Boku, N. et al. Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study. Ann. Oncol. 31, S1192–S1192 (2020).
Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398, 27–40 (2021).
Chao, J. et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 7, 895–902 (2021).
Janjigian, Y. Y. et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov. 8, 49–58 (2018).
Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).
Oken, M. M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5, 649–655 (1982).
Kulangara, K. et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch. Pathol. Lab. Med. 143, 330–337 (2019).
Seymour, L. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18, e143–e152 (2017).
This study was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Y.Y.J. was additionally supported by Memorial Sloan Kettering Cancer Center National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748. We thank the patients and their families and caregivers for participating in the study; the investigators and site personnel; and the following employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA: C. S. Shih for study oversight and M. A. Leiby for medical writing and editorial assistance.
Y.Y.J. has received research funding to the institution from Merck Sharp & Dohme, the National Cancer Institute, the US Department of Defense, Cycle for Survival, Fred’s Team, Rgenix, Bayer, Genentech/Roche, Bristol-Myers Squibb, and Eli Lilly, has served on advisory boards for Rgenix, Merck Serono, Bristol-Myers Squibb, Eli Lilly, Pfizer, Bayer, Imugene, Merck Sharp & Dohme, Daiichi-Sankyo, Zymeworks, SeaGen, Basilea Pharmaceutical and AstraZeneca, and has equity in Rgenix. A.K. has received research funding to the institution from Merck Sharp & Dohme, Ono Pharmaceutical Co., Ltd. and Taiho Pharmaceutical Co., Ltd., and received honoraria for lectures, presentations, speakers’ bureaus, or educational events from Ono Pharmaceutical Co., Ltd. and Taiho Pharmaceutical Co., Ltd. P.Y. has received research funding to the institution and travel support from Merck Sharp & Dohme. N.L. has received research funding to the institution from Merck Sharp & Dohme. S.L. has received research funding to the institution from Merck Sharp & Dohme, Amgen, Merck Serono, Bayer, Roche, Lilly, AstraZeneca, and Bristol-Myers Squib, consulting fees from Amgen, Merck Serono, Lilly, AstraZeneca, Incyte, Daiichi Sankyo, Bristol-Myers Squibb, and Servier, and payment or honoraria for lectures, presentations, speakers’ bureaus, or educational events from Roche, Lilly, Bristol-Myers Squibb, Servier, Merck Serono, Pierre-Fabre, GSK, and Amgen. O.K. has received research funding to the institution from Merck Sharp & Dohme. O.B. has received research funding to the institution from Merck Sharp & Dohme, has received honoraria for serving as a speaker from Eli Lilly, travel support from Bristol-Myers Squibb and Roche, participated as an advisor for Bristol-Myers Squibb and Roche, and has a leadership role in the Sociedad Chilena de Oncología Medica. Y.B. has received research funding to the institution from Merck Sharp & Dohme. L.S. has received research funding to the institution from Merck Sharp & Dohme, Beijing Xiantong Biomedical Technology, Qilu Pharmaceutical, ZaiLab Pharmaceutical (Shanghai), Jacobio Pharmaceuticals, and Beihai Kangcheng (Beijing) Medical Technology, has received consulting fees from Merck Sharp & Dohme, Merck, Mingji Biopharmaceutical, Haichuang Pharmaceutical, Harbour BioMed, and Boehringer Ingelheim, has received payment for speakers bureaus from Hutchison Whampoa, Henrui, ZaiLab, and CSTONE Pharmaceutical, and has participated on an advisory board for Rongchang Pharmaceutical, Zailab, and CSTONE Pharmaceutical. Y.T. has received research funding to the institution from Merck Sharp & Dohme. L.S.W. has received research funding to the institution from Merck Sharp & Dohme. J.X. has received research funding to the institution from Merck Sharp & Dohme. K.S. has received research funding to the institution from Merck Sharp & Dohme, Astellas, Lilly, Ono, Sumitomo Dainippon, Daiichi Sankyo, Taiho, Chugai, Medi Science, and Eisai, has received consulting fees from Astellas, Lilly, Bristol-Myers Squibb, Takeda, Pfizer, Ono, Merck Sharp & Dohme, Taiho, Novartis, AbbVie, GlaxoSmithKline, Daiichi Sankyo, Amgen, and Boehringer Ingelheim, and has received honoraria for lectures from Novartis, AbbVie, and Yalkult. S.Q. has received consulting fees from Merck Sharp & Dohme for serving on an advisory board. E.V.C. has received funding to the institution from Merck Sharp & Dohme, Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Ipsen, Lilly, Merck KGaA, Novartis, Roche, and Servier and has received consulting fees from Array, Astellas, AstraZeneca, Bayer, Beigene, Biocartis, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Halozyme, GSK, Incyte, Ipsen, Merck Sharp & Dohme, Merck KGaA, Novartis, Pierre-Fabre, Roche, Servier, Sirtex, and Taiho. J.T. has received funding to the institution from Merck Sharp & Dohme, has received consulting fees from Array Biopharma, AstraZeneca, Avvinity, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd., Genentech Inc., HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, IQVIA, Lilly, Menarini, Merck Serono, Merus, Merck Sharp & Dohme, Mirati, Neophore, Novartis, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, SeaGen, Servier, Taiho, Tessa Therapeutics, and TheraMyc, and has received payment for educational collaboration with Imedex, Medscape Education, MJH Life Sciences, PeerView Institute for Medical Education, and Physicians Education Resource (PER). L.L. receives salary for full-time employment from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. S.S. receives salary for full-time employment from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and owns stock and/or has stock options in Merck & Co., Inc., Kenilworth, NJ, USA. P.B. receives salary for full-time employment from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and owns stock and/or has stock options in Merck & Co., Inc., Kenilworth, NJ, USA. H.C.C. has received funding to the institution from Merck Sharp & Dohme, Lilly, GlaxoSmithKline, Merck-Serono, Bristol-Myers Squibb/Ono, Taiho, Amgen, BeiGene, Incyte, and Zymeworks, has served on advisory boards for Taiho, Celltrion, Merck Sharp & Dohme, Lilly, Bristol-Myers Squibb, Merck-Serono, Gloria, BeiGene, Amgen, and Zymeworks, and has received honoraria for lectures from Merck-Serono and Lilly. Y.Y.J, A.K., P.Y., N.L., S.L., O.K., O.B., Y.B., L.S., Y.T., L.S.W., J.X., K.S., S.Q., E.V.C., J.T., L.L., S.S., P.B., and H.C.C. received medical writing support for this manuscript (no payment) from Merck Sharp & Dohme.
Peer review information Nature thanks Myriam Chalabi, Florian Lordick, Vicky Wu and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data figures and tables
Extended Data Fig. 1 Treatment difference in objective response in subgroups of the efficacy population.
Response was assessed per RECIST, version 1.1, by blinded, independent central review. The estimated treatment difference between the pembrolizumab and placebo groups in the overall population was calculated using the Miettinen and Nurminen method stratified by geographic region (Australia/Europe/Israel/North America [Aus/Eur/Isr/NAm] vs Asia vs rest of world), PD-L1 combined positive score ([CPS]; ≥1 vs <1), and chemotherapy choice (5-fluorouracil plus cisplatin [FP] vs capecitabine plus oxaliplatin [CAPOX]); differences in subgroups were calculated using the unstratified Miettinen and Nurminen method. The efficacy population included the first 264 participants randomly allocated to treatment. The treatment regimen included trastuzumab and chemotherapy in both groups. Diamonds represent the estimated treatment difference in objective response, the error bars represent the 95% confidence interval (CI) of the estimated treatment difference, and the region shaded in dark grey represents the 95% CI for the treatment difference in the overall population. ECOG, Eastern Cooperative Oncology Group; GEJ, gastro-oesophageal junction; IHC, immunohistochemistry; ISH, in situ hybridization.
About this article
Cite this article
Janjigian, Y.Y., Kawazoe, A., Yañez, P. et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 600, 727–730 (2021). https://doi.org/10.1038/s41586-021-04161-3
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Journal of Hematology & Oncology (2022)
Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study
BMC Gastroenterology (2022)
Nature Reviews Clinical Oncology (2022)
Nature Reviews Gastroenterology & Hepatology (2022)
Essential news and practice changing trials in oesophageal, gastroesophageal junction and gastric cancer in 2021
memo - Magazine of European Medical Oncology (2022)